Japan’s national health insurance will cover Novartis' gene therapy Zolgensma for spinal muscular atrophy patients under the age of two starting as early as May 20, as reported in The Japan Times.
Novartis expects that the one-time therapy, which will cost JPY 167 million per treatment, will be administered to about 25 patients per year in Japan, estimating annual sales of JPY 4.2 billion.
According to the news source, Zolgensma will be the most expensive medication funded by the public system in Japan.
The previous most expensive drug in Japan was Novartis' Kymriah, approved last May to treat leukemia and other hematologic cancers, at JPY 33.49 million.
To read more NewsPoints articles, click here.